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Abstract
Background: Several viruses with known oncogenic potential infect prostate tissue, among these are the 
polyomaviruses BKV, JCV, and SV40; human papillomaviruses (HPVs), and human cytomegalovirus (HCMV) infections. 
Recently, the Xenotropic Murine Leukemia Virus-related gammaretrovirus (XMRV) was identified in prostate tissue with 
a high prevalence observed in prostate cancer (PC) patients homozygous for the glutamine variant of the RNASEL 
protein (462Q/Q). Association studies with the R462Q allele and non-XMRV viruses have not been reported. We 
assessed associations between prostate cancer, prostate viral infections, and the RNASEL 462Q allele in Mexican cancer 
patients and controls.
Methods: 130 subjects (55 prostate cancer cases and 75 controls) were enrolled in the study. DNA and RNA isolated 
from prostate tissues were screened for the presence of viral genomes. Genotyping of the RNASEL R462Q variant was 
performed by Taqman method.
Results: R/R, R/Q, and Q/Q frequencies for R462Q were 0.62, 0.38, and 0.0 for PC cases and 0.69, 0.24, and 0.07 for 
controls, respectively. HPV sequences were detected in 11 (20.0%) cases and 4 (5.3%) controls. XMRV and HCMV 
infections were detected in one and six control samples, respectively. The risk of PC was significantly increased (Odds 
Ratio = 3.98; 95% CI: 1.17-13.56, p = 0.027) by infection of the prostatic tissue with HPV. BKV, JCV, and SV40 sequences 
were not detected in any of the tissue samples examined.
Conclusions: We report a positive association between PC and HPV infection. The 462Q/Q RNASEL genotype was not 
represented in our PC cases; thus, its interaction with prostate viral infections and cancer could not be evaluated.
Background
The contribution of immune and inflammatory
responses to the development of cancer has been well
recognized in different human tumors [1]. Viral infec-
tions may lead to chronic or recurrent inflammation of
the prostate and initiate or promote carcinogenesis [2-6].
Infections of the prostate with polyomaviruses (BK, JC,
and SV40), human papillomaviruses (HPVs), and mem-
bers of the herpesvirus family (HHV-8, HCMV, Epstein
Barr virus) have been previously described [4,7-11]. Viral
products such as the large T antigen of polyomaviruses,
or the E6 and E7 proteins of HPVs are able to induce cell
transformation and interact with the signaling capacity of
the interferon pathway in a synergistic manner [10].
The inflammatory etiology of prostate cancer (PC) is
supported by the fact that the candidate gene for heredi-
tary PC at the HPC1 locus is RNASEL, which is involved
in antiviral and antiproliferative roles of interferons [12-
15]. The R462Q variant of the RNASEL gene has been
reported to occur in 13% of sporadic cases of PC [16].
The enzyme activity of this variant is reduced about two-
thirds and this may impact cellular response against viral
infection [17]. The RNASEL variant R462Q is suggested
to increase susceptibility for PC and has been associated
with an increase in prevalence of the Xenotropic Murine
Leukemia Virus-related gammaretrovirus (XMRV)
[7,9,11]. No study has reported relationships among the
variant, other viral infections, and PC. In the present
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cancer and the RNASEL variant are assessed.
Methods
Patients and samples collection
The study was approved by the institutional review board
of University Hospital of Universidad Autonoma de
Nuevo Leon (ID number: B104-001/B107-001). All
patients provided written informed consent prior to par-
ticipation.
We enrolled one hundred thirty subjects who under-
went transrectal biopsy (TRB) following confirmed clini-
cal criteria [serum prostate specific antigen (PSA) value
≥4 ng/mL or abnormal digital rectal examination (DRE)],
or transurethral resection (TURP) at our institution,
between October 2006 and July 2007 for this population
based case-control study. Criteria guidelines for TURP
were: refractory urinary retention (at least failure in one
attempt of catheter removal), recurrent urinary infection
secondary to benign prostatic hyperplasia (BPH), recur-
rent macrohematuria secondary to BPH, bladder calculi
secondary to prostatic enlargement, renal insufficiency
secondary to BPH, and large or multiple diverticuli sec-
ondary to BPH. The case group included all subjects with
histopathologic diagnosis of PC. The control group con-
sisted of subjects who underwent a TRB or TURP, but
had no pathological evidence of PC.
Venous blood samples for PSA determination and DNA
extraction were drawn from each participating subject
before their procedure. A questionnaire consisting of
demographic data, risk factors, and urologic information
was administered. PSA concentration was determined
from serum samples by the IMMULITE 1000 PSA solid-
phase chemiluminiscent immunometric assay. Sample
collection was performed under local anesthesia and
through the standard octant technique using an 18 gauge
biopsy needle and a biopsy gun and eight cylinders were
taken for histological diagnosis. Two additional cylinders
from the right and left prostate lobes were taken for viral
sequence identification. Fragments of 0.5 × 0.5 cm were
taken from prostate tissue samples obtained by TURP for
viral evaluation. All pathological examinations were per-
formed by a single pathologist (RGG). Study subjects
were not followed thereafter.
Nucleic acid extraction
DNA from blood samples was isolated using a standard
phenol/chloroform protocol, and DNA/RNA extraction
of snap-frozen tissue samples was performed using the
Trizol reagent (Invitrogen, Carlsbad, CA). Samples were
homogenized and extracted according to the manufac-
turer's specifications. Quantity and quality of each extrac-
tion were determined using a spectrophotometer. PCR
amplification of the GAPDH gene was performed to rule
out the presence of PCR inhibitors.
Genotyping
The evaluation of the R462Q variant (rs486907) of RNA-
SEL was performed using the Taqman assay (Applied
Biosystems: ABI, Foster City, CA), as reported by Uris-
man et al. [11]. In the first stage, 10 ng of DNA were
amplified by allele-specific PCR. In a second step, allelic
discrimination was made using the StepOne RT-PCR sys-
tem with the StepOne v2.0 software (Applied Biosys-
tems).
Viral sequence detection
Before screening the prostate tissue for viral DNA, a vali-
dation stage for selected protocols for virus identification
was performed to establish the copy detections limits.
This was achieved through conventional PCR amplifica-
tion, using serial dilutions of control plasmids for each
virus consisting of 600,000 to 60 viral copies (Additional
file 1: Table s1). The reaction products were electro-
phoresed through 3% agarose gels and visualized by
ethidium bromide staining.
Viral sequences were identified in prostate tissue by
nested PCR as previously described [4,8,11]. Briefly, 500
ng of DNA isolated from the prostate were subjected to
PCR amplification designed to detect polyomaviruses
and HPV [4,8,11]. For XMRV screening, 1 μg of RNA was
reverse transcribed using the SSIII system (Invitrogen)
and 2 μL of the cDNA reaction were used in the protocol
described by Urisman et al. [11]. The HCMV detection
was performed in two amplification rounds using sets of
primers specific for the UL3 region, which produced
amplicons of 420 and 188 bp, consecutively. The Addi-
tional file 1 provides information on primer sequences,
regions, sizes of amplified products for each virus (Addi-
tional file 1: Table s1), and plasmids used as positive con-
trols during the viral screening (Additional file 1: Table
s2). For quality control purposes, pre-PCR, processes,
PCR amplification, and post-PCR amplicon analysis were
performed in separate areas, samples were run in dupli-
cate, and negative controls were included in each experi-
ment.
Sequencing and viral Genotyping
PCR products from samples that were positive for viral
sequences were purified by Wizard SV and PCR Clean-
Up System (Promega, Madison WI). Direct sequencing
was performed with the BigDye® Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems) and analyzed using
the Avant 3100 Genetic Analyzer. Sequences were com-
pared with the reported reference sequences for each
virus.
HPV DNA genotypes were distinguished using the Lin-
ear Array HPV Genotyping Test (Roche Diagnostics,
Basel, Switzerland), according to the manufacturer's
instructions and the test results were validated for two
samples by sequencing.
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Cases and controls were compared using univariate
methods. An independent t-test was performed for age
and PSA comparison and the Mann-Whitney U test was
used for comparisons of rank values of median values.
Genotype distribution was checked for Hardy-Weinberg
equilibrium by the exact test. A Chi square test was per-
formed to test the relationship between Genotype-PC,
Genotype-Infection and Infection-PC. Multivariate logis-
tic regression was used with PC as the dependent vari-
able. Two-sided p values < 0.05 were considered
statistically significant.
Results
Clinical characteristics of the study sample
A total of 130 men (55 prostate cancer cases and 75 con-
trols) were enrolled in the study. The majority (92.3%) of
the subjects were from northwestern Mexico (states of
Zacatecas, San Luis Potosi, Tamaulipas, Coahuila, and
Nuevo Leon). For men with PC, 47.3% were older than 70
years of age while 24.0% of controls were older than 70
years. The mean age for cases was 71 years (range: 36-88)
and the mean age for controls was 66 years (range: 50-88),
p = 0.003. There was a statistical difference in PSA values
between case and control groups (p < 0.001). The median
PSA value was 18.30 ng/ml (range: 0.16-1062.00 ng/ml)
for cases and 6.70 ng/ml (range: 0.20-25.99 ng/ml) for
controls. Most men with PC had PSA values >10.0 ng/ml
(Table 1).
The most common pathological diagnosis in the con-
trol group was chronic prostatitis (84%), which was found
in association with normal prostate tissue (41%), hyper-
plastic prostatic tissue (28%), and atrophic tissue (15%).
Only 10 subjects (13%) had a histological diagnosis of
normal prostatic tissue. As listed in Table 1, all PC cases
have Gleason scores ≥6, with 35 (63.6%) having scores >7.
PSA values ≤10 ng/ml were observed in 13/55 (23.6%) of
men with Gleason scores ≥6. Five cases had PSA values
≤4.0 ng/ml, three of them with Gleason scores ≥9.
R462Q Genotyping
All DNA/RNA samples demonstrated amplification of
the GAPDH gene and were therefore used for subsequent
analyses. Frequencies of the RNASEL R462Q genotypes
R/R, R/Q, and Q/Q were 0.62, 0.38 and 0.0 for cases and
0.69, 0.24 and 0.07 for controls, respectively. Genotype
frequencies for the control group did not depart from
Hardy-Weinberg equilibrium by the exact test (p= 0.1),
and due to the lack of representation of the Q/Q genotype
in the PC cases, the association between the RNASEL
R462Q variant and PC could not be determined. We also
tested the association between PC or viral infection and
R462Q genotype. For this association, frequencies of the
R/Q and Q/Q genotypes were grouped and compared
with the R/R frequencies. No associations with PC (p =
0.48) or viral infection (p = 0.34) were found in this subset
analysis.
Viral sequence detection
Specific PCR sequencing assays were standardized for
each virus using positive controls (see Material and
Methods). Detection limits of nested PCR protocols were
established on 30 copies for the polyomaviruses and 60
copies for the HPV, XMRV, and CMV (data not shown).
The presence of BKV, JCV, and SV40 was not detected
in any of the 130 prostatic tissues examined. Viral
genomes for XMRV and HCMV were detected in one
(1.33%) and six (8.0%) control tissues respectively, but not
in the prostate tumors. The presence of HPV sequences
was detected in 15 subjects (11.5%) of which 11 (73.0%) of
them were cases and 4 (27.0%) controls. Genotype distri-
bution of XMRV, HCMV and HPV positive samples is
outlined in Table 2. Nine HPV positive subjects with PC
were homozygous R/R for the RNASEL R462Q genotype
and two were heterozygous R/Q for the RNASEL R462Q
variant. HPV infection significantly increased the odds of
PC by 4.4 times in our population (95% CI: 1.33 to 14.80,
p = 0.021). Due to the difference in age in the study
groups, adjustments for age were included in the multi-
variate logistic regression model. The odds ratio for HPV
infection and PC was 3.98 (95% CI: 1.17 to 13.56, p =
0.027).
Differences between infection with these viruses and
serum PSA levels were not found (p = 0.9). There were no
associations found between RNASEL R462Q genotype
and the presence of any viral infection (p = 0.4).
Given the limited size of the tissue specimens, HPV
sub-typing was performed on only six samples (five cases
Table 1: Comparison of study groups by PSA value and Gleason score
PSA value (ng/ml) Cases Controls Total Gleason score (frequency)
0.1 - 4.0 5 24 29 6(2), 9(1), 10(2)
4.1 - 8.0 4 27 31 6(3), 9(1)
8.1 - 10.0 4 6 10 6(1), 8(2), 9(1),
>10.0 42 18 60 6(5), 7(9), 8(10), 9(14), 10(4)
Total 55 75 130 55
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screened for ten different types of HPV; seven of them
were oncogenic high risk HPVs (33, 45, 52, 58, 66, 68, and
83) and three were oncogenic low risk viruses (44, 81,
CP6108). Three samples showed infection with multiple
HPV types, while the remaining three had a single HPV
type infection. Oncogenic high risk HPVs were found in
four of the five cancers and in the control.
Some limitations of the study include the small sample
size which may introduce bias into the statistical analyses
performed. However, in most of the cases we used a low
quantity of prostate tissue (two TRB cylinders) for the
virus screening and it could to enhance the differences in
virus detection between studies. We included 18 control
subjects with serum PSA values ≥10 ng/ml, despite the
high probability (≥50%) of detecting cancer in individuals
who have PSA values ≥10 ng/ml [18]. Since most of these
subjects did not have PC diagnosis in any of two consecu-
tive TRB procedures, they were not excluded from the
study. Their high PSA values may be related to a different
pathology, such as prostatitis, hyperplasia, or atrophy,
which may impact the PSA levels [19,20]. Moreover,
exclusion of these subjects from the OR calculations con-
firms the association between HPV infection and PC (OR
= 4.8, 95% CI: 1.25-18.37, p = 0.03).
Discussion
Genetic factors, such as the R462Q variant of RNASEL,
may play a role in the etiology of PC. In addition, viral
infections of the prostate have also been suggested as
important virally-related risk factors for PC, particularly,
infections with HCMV, JCV and BKV, high risk HPV, and
more recently, XMRV [4,5]. However, studies designed to
replicate the association of either the R462Q variant or
viral infections with PC have yielded conflicting results
worldwide. This current study analyzed associations
between viral infections, the R462Q variant of RNASEL,
and PC. Our results showed a low frequency of Q/Q
homozygous subjects (6.7% in controls and 0.0% in cases)
compared with those found in previous studies (5.7-
13.3%) [21] and associations with this genotype could not
be demonstrated. This low genotype frequency may be
explained by racial/ethnic variations.
Detection of viral genome sequences in prostatic tissue
was restricted to HCMV (4.6%), XMRV (0.8%), and HPV
(11.5%). The only XMRV positive sample was from a con-
trol subject with the RNASEL R462Q R/R genotype (64
years old, PSA value of 0.64 ng/ml, and normal prostate
tissue by histology). The relationship between viral infec-
tion and the R462Q Q/Q genotype has been reported for
the XMRV only, and thus no comparison had been made
for other prostate viral infections.
A comparison on the prevalences of HPV, HCMV, poly-
omaviruses, and HPV in prostatic tissue (including ours)
is shown in Table 4. HPV DNA sequences were found in
11/55 cases (20.0%) and 4/75 (5.3%) controls. This infec-
tion increases the risk of PC by 3.98 times (p = 0.027).
These results are consistent with the data reported by
Table 3: Summary of HPV typing and characteristics of clinical specimens
Group Age Gleason Score PSA value (ng/ml) HPV type
Case 81 8 (4+4) 47.1 58, 52, 66
Case 77 9 (4+5) 6.69 81
Case 57 10 (5+5) 26.2 45, CP6108
Case 79 10 (5+5) 0.16 68, 33
Case 75 9 (5+4) 100 44
Control 72 - 12.1 83
Table 2: Genotype distribution of samples positive for viral detection
CASES TOTAL CONTROLS TOTAL
Virus (+)/Genotype R/R R/Q Q/Q R/R R/Q Q/Q
Py (BK, JC, SV40) 0 0 0 0 0 0 0 0
HPV 9 2 0 11 4 0 0 4
HCMV 0 0 0 0 3 2 1 6
XMRV 0 0 0 0 1 0 0 1
TOTAL 9 2 0 11 8 2 1 11
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tion between the presence of HPV sequences and pros-
tate carcinomas in Argentina (41.5% prevalence in PC
cases). Zambrano et al. [4] detected a high HPV preva-
lence in prostate tissue in six of 12 PC patients using PC
tissue and urine specimens. Conversely two independent
studies separately reported by Bergh and Sfanos in Swe-
den and the United States did not find HPV sequences in
any of the 352 and 200 prostatic tissue samples screened,
respectively [23,24] (Table 4).
Discrepancies may be explained by technical differ-
ences in the viral detection methods or differences in sex-
ual behavior in the study populations. HPV prevalences
in healthy men demonstrate large variations worldwide,
ranging between 3% and 45% [25-27]. There are no data
available about prostate HPV infection in Mexico; how-
ever, our results are in accordance with previous reports
of the high HPV prevalence (43-46%) in exfoliated cells
from the urethra-coronal sulcus of sexually active sub-
jects and healthy military men in Mexico, respectively
[27].
We found different types of oncogenic high risk HPV
without the presence of a predominant HPV type, sug-
gesting that the HPV association with PC is not due to
specific type of HPV, as implied in previous reports, par-
ticularly since HPV16 or HPV18 were not detected in this
study [4,28]. The remarkable incidence of multiple HPV
infections reported here, suggest a relationship with PC
that deserves further analyses.
Most of the tissue samples used were TRB specimens. It
has been suggested that viral contamination of prostate
tissue by HPV and polyomaviruses (detectable in urethral
or anal tissues), could occur from neighboring tissues
during the sampling procedure; but differences in virus
prevalence between case and control groups minimizes
the contamination possibility.
Table 4: Comparative summary and main findings of prostate viral infection reports
Country/Study 
Description
Pathogen Samples (+) Total Findings Reference
Sweden/201 prostate tissue 
samples from patients with 
BPH that later progressed to 
PC and 201 matched controls 
that did not.
Epstein-Barr Virus.
JCV.
BKV, HPVs, CMV.
Adenovirus, HSV1 and 2
C.albicans.
31
10
0
0
2
43
(352)
There were no differences in 
the prevalence of adenovirus, 
herpesvirus, papillomavirus, polyoma
virus and C. albicans DNA.
Bergh J. 
British 
Journal of 
Cancer 2007.
Baltimore, USA/30 PC 
subjects for bacterial DNA 
and 200 PC cases for 
viral-parasite 
DNA detection.
BKV.
Chlamydia T.
CMV.
Epstein-Barr Virus.
HPVs, XMRV.
1
1
1
16
0
18
(200)
Most prostatectomies (87%) 
contain bacterial DNA from 
one or more species. The 
majority of individual tissue 
core samples were negative, 
suggesting regional heterogeneity 
in the presence of bacteria 
and a lack of a generalized 
or ubiquitous prostatic flora.
Sfanos KS. 
The Prostate 
2008.
Greece/42 samples 
of prostatic 
malignancies.
BKV.
JCV.
HPVs..
8
0
2
10
(42)
BKV was frequently detected 
and could play a relevant role 
in the development and 
progression of human PC, 
whereas HPV does not seem 
to be implicated in this type of 
human neoplasia.
Balis V. 
Int J Biol 
Markers. 2007.
LongBeach, USA/
12 PC Fresh frozen 
tissues and 20 
paraffin-embedded 
archival samples.
HPVs.
JCV.
BKV.
0 (20), 6 (12)
10 (20),6 (12)
0 (20), 3 (12)
10 (20)
And
7(12)
The prostate is a complex 
habitat where mixed 
infections with oncogenic 
DNA viruses frequently 
occur and opens the 
discussion to the 
potential role of these 
viruses in the PC.
Zambrano A, 
Prostate 
2002.
Monterrey, 
Mexico/55 
Cases of PC 
and 75 Controls.
JCV, BKV, SV40.
HPVs.
HCMV.
XMRV.
0
15
6
1
22
(130)
HPV frequency was 
significantly higher in PC 
cases than in controls; 
this finding suggests 
their participation in 
PC develpment or tumor progression.
This work.
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viral infection is the interferon response, as E6 and E7
HPV proteins can inhibit the signaling capacity of inter-
feron pathway [10]. This may be associated with disease
aggressiveness. Our results indicated no association
between HPV infection and tumor aggressiveness repre-
sented by Gleason score.
In this study, polyomavirus genomes were not detected
in any of the 130 evaluated tissue samples; however, six
HCMV positive samples were detected in the control
group. Absence of HCMV, polyomaviruses, and XMRV in
tumor prostate tissue suggests that they are not associ-
ated with PC in Mexican population, though positive
control samples (with the exception of the XMRV's posi-
tive sample) demonstrated chronic prostatitis that may
evolve to malignancy, as suggested by some authors [2-6].
Our results for the XMRV virus in a Mexican sample
differ from those reported by Urisman et al. [11] who
described 8 out of 20 XMRV positive samples in Q/Q
homozygous subjects versus 1 out of 52 positive samples
in R/R subjects. XMRV prevalence in sporadic PC cases
has been notoriously lower than reported by Urisman.
Fischer et al. [9] identified two XMRV positive samples in
157 prostatic tissue samples and none in eleven Q/Q
homozygous tissue samples included in the study per-
formed in German subjects. In an additional report from
this country, Honh et al. [29] could not demonstrate the
presence of the XMRV in 589 prostate tumor samples
using real-time PCR. D'arcy et al. [7] reported no evi-
dence of XMRV in Q/Q Irish PC patients. A recent report
by Schlaberg et al. [30] describes no association between
XMRV infection and RNASEL R462Q genotype; but in
contrast, found association between retroviral infection
and PC. Mutations in the RNASEL locus other than the
R462Q variant may affect either the PC risk or the sus-
ceptibility to viral infections of the prostate, but they were
not aimed in this study.
Conclusions
We found association between PC and prostate infection
by HPV. The 462Q/Q RNASEL genotype was not repre-
sented in PC cases, therefore the interactions among
prostate viral infections, PC, and the 462Q allele could
not be proven.
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